Angle raises funds with placing

Angle, a specialist medtech company, has placed 4.53m new ordinary shares at 50p each, representing a discount of 17.4 per cent on the mid-price of 60.50p per share at close of business on Wednesday.

Angle, a specialist medtech company, has placed 4.53m new ordinary shares at 50p each, representing a discount of 17.4 per cent on the mid-price of 60.50p per share at close of business on Wednesday.

Net of costs, the placing raised £2.2m, which will be used to strengthen the company's financial position and support the launch of its Parsortix cancer diagnostic product for the research market.

The new shares represent around 10% of the enlarged issued share capital, with the total number following admission being 45.243m.

Founder and Chief Executive, Andrew Newland, said: "We are delighted that shareholders have recognised the progress made against milestones and have continued to support the company. The funds raised will enable us to continue the strong progress of our Parsortix system as we move into a new phase of product launch, validation and regulatory approval."

Angle is focused on achieving early sales in the research market and taking the necessary steps to allow Parsortix to be used in the much larger clinical market in the treatment of patients.

The group explained: "To support this work and to put the company in a stronger position from which to negotiate commercial deals in relation to its Parsortix platform, the board considered it appropriate to raise a somewhat larger sum of funding."

Half year losses narrowIn the six months ended October 31st, the group delivered a half year loss of £0.4m, compared to £1.8m the same period the previous year.

Revenue for the period fell from £0.7m to £0.47m, but this was offset by the charge in fair value, which came in at £0.29m, compared to -£1.35m in 2011.

The share price fell 6.61% to 56.50p by 13:45.

NR

Recommended

The MoneyWeek Podcast: picking stocks is fun, but you need to do your homework
Investment strategy

The MoneyWeek Podcast: picking stocks is fun, but you need to do your homework

John Stepek talks to Steve Clapham, investor, analyst and author of The Smart Money Method, about the dangers in picking individual stocks and why you…
8 Apr 2021
BP looks set to return more money to shareholders as it beats expectations
Energy stocks

BP looks set to return more money to shareholders as it beats expectations

Oil major BP is to embark on a share buyback programme after significantly reducing its debts. Saloni Sardana looks at what it means for your portfoli…
6 Apr 2021
Deliveroo has hit the market – but it’s not getting the warmest welcome
UK stockmarkets

Deliveroo has hit the market – but it’s not getting the warmest welcome

Food delivery company Deliveroo made its debut on the stockmarket this morning. But with the share price sliding by 30% straight away, it’s not made t…
31 Mar 2021
Three stocks to buy now that will come back stronger after Covid-19
Share tips

Three stocks to buy now that will come back stronger after Covid-19

Professional investor Ed Wielechowski of Odyssean Capital, chooses three compelling stocks that should thrive in a post-pandemic world.
29 Mar 2021

Most Popular

Lab-grown meat: how “moo’s law” will drive innovation
Soft commodities

Lab-grown meat: how “moo’s law” will drive innovation

Jim Mellon and Anthony Chow, co-founders of Aim-listed Agronomics, explain why they believe that “cellular agriculture” will benefit from massive long…
16 Apr 2021
The bitcoin bubble will burst: here’s how to play it
Bitcoin

The bitcoin bubble will burst: here’s how to play it

The cryptocurrency’s price has soared far beyond its fundamentals, says Matthew Partridge. Here, he looks at how to short bitcoin.
12 Apr 2021
Lab-grown meat: the new agricultural revolution
Soft commodities

Lab-grown meat: the new agricultural revolution

Vegan alternatives are taking off, but the future of food technology lies in lab-grown meat – cultivating steaks and burgers from animal cells, says A…
16 Apr 2021